About PanTera
PanTera is a Healthcare company based in Mol (Belgium) founded in 2022. It operates as a radiotheranostics using actinium-225 are developed for targeted cancer treatments. PanTera has raised $102.58 million across 2 funding rounds from investors including EQT, Eurazeo and PMV. Its chief executive is Sven van den Berghe. PanTera offers products and services including Actinium-225 Supply. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Ariceum Therapeutics and 3 more; 7 of its 8 listed competitors have raised funding.
Company details
PanTera was founded in 2022 in Mol, Belgium, within the biotechnology sector focused on radiotheranostics. Actinium-225 isotope is utilized by the company to enable localized cell killing in treatments for specific cancers. Targeted therapies are provided to address patient needs through precise cellular targeting. Operations are centered on isotope-based solutions, with Sven van den Berghe serving as CEO. The domain pantera-life.com is maintained for related information.
- Headquarters Mol, Belgium
- SectorsHealthcare
- Email••••••••
- Website pantera-life.com
- Social LinkedIn
- Total Equity Funding$102.58M (USD)
in 2 rounds
- Latest Funding Round$102.58M (USD), Series A
Sep 2024
- InvestorsEQT
& 5 more
Products & Services of PanTera
PanTera offers a comprehensive portfolio of products and services, including Actinium-225 Supply.
Provides actinium-225 for targeted cancer radiotherapy treatments.
Funding Insights of PanTera
PanTera has successfully raised a total of $102.58M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $102.58 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $102.58M
- Total Rounds 2
- Last Round Series A — $102.58M
- First Round $37.28M
(Sep 2024)
- Investors Count 6
All 2 funding rounds of PanTera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $37.28M | Debt – Conventional | – | – | – |
| Sep 2024 | $102.58M | Series A | – | EQT |
6 investors in total: 6 institutional.
Investors in PanTera
PanTera has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include EQT, Eurazeo and PMV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Private equity and debt investments are managed across multiple sectors. | 1969 | eurazeo.com | Paris, France | |
Sustainable investing in conscious consumer, energy transition, and healthy living sectors. | 2011 | korys.be | - | |
Private debt funds are managed across multiple sectors. | 2001 | pmv.eu | Brussels, Belgium | |
Venture capital is invested in multiple sectors by Paladin Capital. | – | paladincapgroup.com | Washington, Dc, United States |
Investor details for PanTera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PanTera
1 people are tracked at PanTera (1 in leadership).
| Name | Role | Group |
|---|---|---|
Sven van den Berghe | CEO | Leadership |
Complete people profiles for PanTera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PanTera
2 dated milestones of PanTera across 2 years, from founding to its latest funding, stage changes and deals.
- Founded PanTera is founded.
- Funding First funding round of $37.3M.
Competitors of PanTera
PanTera has 8 listed competitors in our database, 7 of them funded. They include Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Ariceum Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| sofie.com | 2008 | Culver, United States | $43.1M | 546 | Developer of molecular imaging systems and radio-pharmaceuticals | |
| marianaoncology.com | 2020 | Watertown, United States | $250M | 41 | Targeted radiopharmaceuticals for solid tumors are developed and pioneered. | |
| advancell.com.au | 2019 | Sydney, Australia | $129.42M | – | Radiopharmaceutical company developing targeted alpha therapies for cancer treatment | |
| ariceum-therapeutics.com | 2021 | Berlin, Germany | $51.64M | – | Developer of drugs for systemic targeted radiation therapy to treat cancer | |
| lantheus.com | 2008 | Billerica, United States | – | 834 | Developer of diagnostic imaging agents and targeted therapeutics | |
| a9oncology.com | 2018 | Boston, United States | $261M | – | Radiopharmaceuticals for cancer treatment are developed using peptide-based technologies. | |
| artbio.com | 2021 | Sacramento, United States | $245.3M | – | Alpha radioligand therapies for cancer are developed using lead-212. |
Detailed competitors of PanTera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PanTera
The website of PanTera (pantera-life.com) receives about 4K visits a month.
- Monthly visits4K
▲ 64.3% vs previous month
Top companies in Oncology
10 companies that operate in the same segment as PanTera (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pantera
Complete news archive for PanTera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PanTera
PanTera was founded in 2022 and raised its 1st funding round 2 years after it was founded.
PanTera is headquartered in Mol, Belgium. It is registered at Mol, Antwerp, Belgium.
Sven van den Berghe is the current CEO of PanTera.
PanTera is a funded company, having raised a total of $102.58M across 2 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $37.28M, raised on Sep 2024.
PanTera was founded in 2022 in Mol, Belgium, within the biotechnology sector focused on radiotheranostics. Actinium-225 isotope is utilized by the company to enable localized cell killing in treatments for specific cancers. Targeted therapies are provided to address patient needs through precise cellular targeting. Operations are centered on isotope-based solutions, with Sven van den Berghe serving as CEO. The domain pantera-life.com is maintained for related information.
PanTera's top competitors include Advanced Accelerator Applications, SOFIE and AdvanCell.
PanTera offers Actinium-225 Supply.
PanTera has 6 investors. Key investors include EQT, Eurazeo, PMV, Kurma Partners, and Korys.